Publication Topic

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Sacks NC, Everson K, Emden MR, Cyr PL, Wood DR, Raza S, Wood KA, Pokorney SD. 2020. Disparities in the management of newly diagnosed paroxysmal supraventricular tachycardia for women versus men in the United States. J Am Heart Assoc 9(19):e015910; 10.1161/JAHA.120.0159.

Bylsma LC, Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, Rosenthal A. 2020. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Prac Thromb Haemostas 4(4):628-635; doi: 10.1002/rth2.12333.

Patel P, Jiang X, Nicholson G, Frankenfeld C, Iglesias-Rodriguez, Fryzek J, Su J. Medically attended anxiety or depression is increased among newly diagnosed patients with cold agglutinin disease (CAD). Virtual presentation to American Society of Hematology, 2020.

Frankenfeld CL, Menon N, Leslie TF. 2020. Racial disparities in colorectal cancer time-to-treatment and survival time for colorectal tumors and diagnosing hospital cancer-related diagnostic and treatment capabilities. Cancer Epidemiol 65:101684, https://doi.org/10.1016/j.canep.2020.101684.

Menon N, Leslie TF, Frankenfeld CL. 2020. Cancer-related diagnostic and treatment capabilities of hospitals in the context of racial residential segregation. Public Health 182(May):95–101; doi: 10.1016/j.puhe.2020.02.004.

Nordyke RJ, Nicholson G, Gage SM, Lithgow T, Himmelfarb J, Rivara MB, Hays RD, Woo K, Peipert JD. 2020. Vascular access-specific health-related quality of life impacts among hemodialysis patients: Qualitative development of the hemodialysis access-related quality of life (HARQ) instrument. BMC Nephrol 14;21(1):16; doi: 10.1186/s12882-020-1683-5. PMID: 31937249.

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. J Oncol Pharmacy Prac (abstract 22), doi:10.1177/1078155219834495.

Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019.